MASATAKA SUZUKI to Immunotherapy
This is a "connection" page, showing publications MASATAKA SUZUKI has written about Immunotherapy.
Connection Strength
0.186
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
Score: 0.156
-
Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen-specific immunotherapy. Head Neck. 2021 07; 43(7):1983-1994.
Score: 0.030